Please assess the completion status of the following clinical trial:

Trial Title: Omega-3 Dietary Supplements in Schizophrenia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: None
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Current DSM-IV-defined diagnosis of schizophrenia, schizophreniform, schizoaffective disorder, psychosis NOS or Bipolar I as assessed using the Structured Clinical Interview for Axis I DSM-IV Disorders;~* Does not DSM-IV criteria for a current substance-induced psychotic disorder, a psychotic disorder due to a general medical condition, delusional disorder, brief psychotic disorder, shared psychotic disorder, or a mood disorder with psychotic features;~* current positive symptoms rated more than 4 (moderate) on one of these BPRS items: conceptual disorganization, grandiosity, hallucinatory behavior, and unusual thought content;~* is in a early phase of illness as defined by having taken antipsychotic medications for a cumulative lifetime period of 2 years or less;~* age 15 to 40;~* competent and willing to sign informed consent; and~* for women, negative pregnancy test and agreement to use a medically accepted birth control method.~Exclusion Criteria:~* serious neurological or endocrine disorder or any medical condition or treatment known to affect the brain;~* any medical condition which requires treatment with a medication with psychotropic effects;~* significant risk of suicidal or homicidal behavior;~* cognitive or language limitations, or any other factor that would preclude subjects providing informed consent;~* medical contraindications to treatment with risperidone (e.g. neuroleptic malignant syndrome with prior risperidone exposure), omega-3 supplements (e.g. bleeding disorder, seafood allergies) or placebo capsules (e.g. allergies to capsule components);~* contraindications to MRI imaging (e.g. presence of a pacemaker);~* lack of response to a prior adequate trial of risperidone;~* taking omega-3 supplements within the past 8 weeks, and~* requires treatment with an antidepressant or mood stabilizing medication.

- Gender: ALL
- Minimum Age: 15 Years
- Maximum Age: 40 Years
- Healthy Volunteers: f

Study Arms:
- Omega-3 capsules & Risperidone (Type: EXPERIMENTAL): Subjects will take 1 capsule in the morning and 1 capsule in the evening. Each capsule contains 370 mg EPA and 200 mg DHA as well as 2 mg/g tocopherol. The study dose will start on day 1 and remain the same throughout the study.
- Placebo & Risperidone (Type: OTHER): Subjects will take 1 capsule in the morning and 1 capsule in the evening.The placebo is a soybean/corn blend (each capsule contains 1000 mg). The study dose will start on day 1 and remain the same throughout the study.

Based on this trial design, predict the completion outcome and termination type (if applicable).